DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Volkswagen Q1 2026 Sales Decline Amid China and U.S. Market Pressures 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees 
Baker Hughes Sells Waygate Technologies to Hexagon for $1.45 Billion 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Anthropic Discusses Frontier AI Model Mythos With Trump Administration Despite Pentagon Ban 
Bristol Myers Squibb acquired RayzeBio for a staggering amount of $4.1 billion. The global biopharmaceutical company is investing to bolster its cancer therapy portfolio and business.
Terms of the Agreement
This Bristol Myers Squibb deal is the latest one that it has signed in less than a week. It has just announced its purchase of Karuna Therapeutics, a drug developer, on Friday, as per Reuters.
With the buyout deal, Bristol Myers will have access to RayzeBio's drug production facility located in Indianapolis, Indiana. It was agreed that the former would pay $62.50 in cash for every share of RayzeBio.
Looking Forward to Growth as Bristol Myers and RayzeBio Merge
Bristol Myers Squibb's acquisition of RayzeBio is a strategic move that aligns with the recent gush of mergers and acquisition agreements in the pharmaceutical industry. The companies' respective management teams believe this deal will fuel growth within the second half of this decade.
"This transaction enhances our increasingly diversified oncology portfolio by bringing a differentiated platform and pipeline, and further strengthens our growth opportunities in the back half of the decade and beyond," Bristol Myers Squibb's chief executive officer, Christopher Boerner, Ph.D., said in a press release. "We look forward to supporting and accelerating RayzeBio's preclinical and clinical programs and advancing its highly innovative radiopharmaceutical platform."
RayzeBio's president and CEO, Ken Song, M.D., further stated, "Despite therapeutic advances in recent years, the need for more effective treatments in solid tumors persists, and radiopharmaceutical therapeutics are positioned to be an important next wave of innovation in oncology therapy."
The biotech firm's chief added, "Bristol Myers Squibb's well-established presence in oncology and deep expertise in developing, commercializing, and manufacturing treatments on a global scale makes it the ideal partner for RayzeBio at this important moment in our evolution and I am very excited to see what our team clinches as part of Bristol Myers Squibb."
Photo by: Bristol Myers Squibb Media Gallery
